Positive clinical results of Palobiofarma´s adenosine A1 antagonist PBF-680 presented at the European Respiratory Society meeting

by Palobiofarma

6 years ago
oral asthma therapy, allergen, adenosine

The results of an allergen POC trial in asthmatics will summarized by Dr. David Ramos, principal investigator of the PBF-680 clinical program, in an oral presentation titled:

Palobiofarma announces positive results from the Phase II clinical trial evaluating the preliminary efficacy and safety of its adenosine A1 receptor antagonist PBF-680 in mild to moderate asthmatics patients

by Palobiofarma

6 years ago
clinical trial, drug, asthmatics

The results confirm a clinically and statistically significant improvement in trough FEV1 of asthmatic patients taking 10mg of PBF-680 for 14 days compared to placebo.

Palobiofarma joins the fight against the Covid-19 pandemia

by Palobiofarma

6 years ago
research, CDTI, covid-19

The company announced the initiation a of a drug discovery program towards the identification of novel oral drugs specifically designed to treat infections caused by Corona viruses.

XOMA and Inveready Acquires Royalty Interest Position in Six Clinical-Stage Assets from Palobiofarma

by Palobiofarma

7 years ago
Novartis, Inveready, tumor, inhibitor, adenosine

XOMA Corporation (NASDAQ: XOMA), announced today it has acquired a royalty interest in six clinical-stage assets targeting the adenosine pathway for $10.0 million from Palobiofarma S.L.One of the asse...

Palobiofarma receives milestone payment from Novartis

by Palobiofarma

10 years ago
Palobiofarma, Novartis, lung cancer, PBF-509, PDR001

The milestone payment is the first from the licensing agreement between the two companies. Under the terms of that agreement, which was signed in September 2015, Novartis has exclusive development and...

Palobiofarma signs licensing agreement to develop novel adenosine-based immuno-oncology treatments

by Palobiofarma

11 years ago
lung cancer, licensing agreement, drug development, PBF-509, Palobiofarma, Novartis

Under the terms of the agreement Novartis will acquire exclusive global rights to develop, manufacture and commercialize Palobiofarma´s adenosine A2Areceptor antagonist PBF-509, currently entering Ph...